```html

Kocher's Disease (Hereditary Hemorrhagic Telangiectasia)

Overview

Kocher’s disease is another name for Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder that causes abnormal blood‑vessel formation (vascular malformations). These malformed vessels are fragile and prone to bleeding, especially on the skin and mucous membranes. HHT is autosomal dominant, meaning a single copy of a mutated gene can cause the condition.

• Prevalence: Approximately 1 in 5,000–8,000 people worldwide are affected, though many remain undiagnosed (Mayo Clinic; WHO).
• Typical age of presentation: Symptoms often appear in adolescence or early adulthood, but some individuals are diagnosed in childhood or later in life.
• Gender: Both males and females are equally affected.

Symptoms

Symptoms result from the tendency of telangiectasias (small dilated vessels) and larger arteriovenous malformations (AVMs) to bleed or shunt blood. Not every patient experiences all manifestations.

Cutaneous and Mucosal Telangiectasias

• Nosebleeds (epistaxis): The most common early sign; 90% of patients experience recurrent episodes.
• Oral and Lip Telangiectasias: Small red spots on the tongue, gums, and lips that may bleed.
• Facial skin lesions: Typically on the nose, cheeks, and chin.

Gastrointestinal Bleeding

• Occult or overt GI bleeding leading to iron‑deficiency anemia, especially after age 30.
• Bleeding sites: stomach, small intestine, colon.

Respiratory System

• Pulmonary AVMs: Abnormal connections between pulmonary arteries and veins causing shortness of breath, clubbing, and risk of paradoxical emboli (stroke or brain abscess).

Neurologic Manifestations

• Cerebral AVMs: Headaches, seizures, or focal neurological deficits.
• Risk of intracranial hemorrhage, though less common than pulmonary AVMs.

Hepatic Involvement

• Hepatic AVMs can cause high‑output cardiac failure, portal hypertension, or biliary disease.

Other Possible Findings

• Finger clubbing (often linked to pulmonary AVMs).
• Heart murmur from high‑output cardiac state.
• Fatigue, weakness, and dizziness secondary to chronic anemia.

Causes and Risk Factors

HHT results from mutations in genes that regulate angiogenesis (the formation of new blood vessels). The three most common genes are:

• ENG (endoglin) – HHT type 1: ~40% of cases; often associated with pulmonary AVMs.
• ACVRL1 (ALK1) – HHT type 2: ~35% of cases; liver involvement is more frequent.
• SMAD4 – Juvenile polyposis/HHT overlap syndrome: Rare, but may cause gastrointestinal polyps.

Risk Factors

• Family history: A first‑degree relative with HHT dramatically increases risk (autosomal dominant inheritance).
• Ethnicity: Certain founder mutations are prevalent in Dutch, French‑Canadian, and Japanese populations.
• Pregnancy: Hormonal changes can exacerbate bleeding, especially epistaxis.

Diagnosis

Diagnosis is clinical, supported by imaging and genetic testing. The Curacao criteria (adopted by the International HHT Society) are the most widely used:

1. Spontaneous recurrent epistaxis.
2. Multiple telangiectasias at characteristic sites (lips, oral cavity, hands, face).
3. Visceral lesions (pulmonary, cerebral, hepatic, gastrointestinal AVMs).
4. First‑degree relative with HHT.

Having ≥ 3 criteria confirms the diagnosis; 2 criteria make it “possible,” and <3 makes it unlikely.

Key Diagnostic Tests

• Genetic testing: Sequencing of ENG, ACVRL1, and SMAD4; useful for family screening (NIH).
• Contrast‑enhanced CT or MRI: Detects pulmonary, cerebral, or hepatic AVMs.
• Contrast echocardiography (bubble study): Screens for pulmonary AVMs by detecting right‑to‑left shunt.
• Endoscopy: Evaluates gastrointestinal telangiectasias if anemia is present.
• Laboratory studies: CBC for anemia, iron studies, and liver function tests if hepatic involvement suspected.

Treatment Options

Management is multidisciplinary, aiming to control bleeding, prevent complications, and improve quality of life.

Medications

• Antifibrinolytics (tranexamic acid): Reduces epistaxis severity; use with caution in patients at risk for thrombosis.
• Hormonal therapy (estrogen‑progestin, tamoxifen): Historically used for epistaxis, but limited by side‑effects.
• Bevacizumab (anti‑VEGF): Intravenous or topical formulations can lessen bleeding from telangiectasias and improve anemia (Cleveland Clinic; recent clinical trials).
• Iron supplementation (oral or IV): Corrects iron‑deficiency anemia; IV iron is preferred when GI bleeding is ongoing.

Procedural Interventions

• Nasal cauterization (laser, electrocautery) or sclerotherapy: First‑line for refractory epistaxis.
• Endoscopic laser ablation: Treats GI telangiectasias.
• Embolization of pulmonary or cerebral AVMs: Minimally invasive occlusion using coils or plugs; reduces risk of stroke, brain abscess, and heart failure.
• Liver transplantation: Reserved for severe hepatic AVM‑related heart failure unresponsive to other measures.

Lifestyle & Supportive Measures

• Maintain humidified indoor air to lessen nasal dryness.
• Avoid nasal trauma (nose picking, aggressive blowing).
• Use saline nasal sprays or gels regularly.
• Adopt a diet rich in iron (red meat, legumes, leafy greens) and consider vitamin C to enhance absorption.

Living with Kocher's Disease (Hereditary Hemorrhagic Telangiectasia)

While HHT is chronic, many patients lead full, active lives with appropriate monitoring and care.

Daily Management Tips

• Track bleeding episodes: Keep a simple diary of epistaxis frequency, duration, and any required interventions.
• Regular monitoring: Annual ENT review, biennial MRI/CT for AVM surveillance, and periodic CBC.
• Iron status: Check ferritin and hemoglobin every 6–12 months; supplement as advised.
• Vaccinations: Ensure up‑to‑date pneumococcal, influenza, and COVID‑19 vaccines—important if lung AVMs are present.
• Pregnancy planning: Discuss risks with a maternal‑fetal medicine specialist; pulmonary AVMs may need embolization before conception.
• Genetic counseling: Offers information for family planning and testing of relatives.
• Support groups: Organizations such as the HHT Foundation International provide community, education, and research updates.

Prevention

Because HHT is genetic, primary prevention is not possible, but secondary prevention (reducing complications) is achievable:

• Early genetic testing of at‑risk family members.
• Prompt treatment of nosebleeds to avoid chronic anemia.
• Screen for pulmonary AVMs before high‑risk activities (scuba diving, high‑altitude travel).
• Control blood pressure and avoid smoking, which can exacerbate vascular fragility.

Complications

If left untreated, HHT can lead to serious health issues:

• Severe iron‑deficiency anemia: May require transfusions.
• High‑output cardiac failure: Result of large hepatic AVMs shunting blood.
• Stroke or brain abscess: From paradoxical emboli crossing pulmonary AVMs.
• Hemorrhagic stroke: Due to ruptured cerebral AVM.
• Pulmonary hypertension: Secondary to chronic hypoxemia.
• Gastrointestinal bleeding: Chronic melena or occult blood loss.
• Pregnancy complications: Increased risk of severe epistaxis, anemia, and AVM rupture.

When to Seek Emergency Care

Early recognition and treatment of these emergencies can be lifesaving.

References

• Mayo Clinic. “Hereditary hemorrhagic telangiectasia.” https://www.mayoclinic.org
• National Institutes of Health (NIH). “Hereditary Hemorrhagic Telangiectasia.” Genetics Home Reference.
• World Health Organization. “Rare Diseases: HHT.” WHO Rare Diseases Database.
• Cleveland Clinic. “Treatment options for HHT.” https://my.clevelandclinic.org
• HHT Foundation International. Clinical Guidelines (2022).
• Gossage JR, Kahn JR. “Hereditary hemorrhagic telangiectasia.” Ann Intern Med. 2021;174(7):1015‑1025.

```